Not medical advice. Cagrilintide is sold for research. This guide does not recommend dosing, diagnosis, or therapy.
Cagrilintide is listed in our catalogue under “Fat Loss / Metabolic.” In scientific publications it is discussed in technical language; this page translates the general themes into everyday wording while staying faithful to research-only framing.
One-paragraph overview from our research datasheet—still scientific, but faster to read than the full mechanism list below.
Cagrilintide (AM833) — long-acting acylated amylin analogue and non-selective AMYR/CTR agonist with 8-day half-life for once-weekly obesity research.
Many readers want context before diving into pathways. The list below summarises what researchers and reviewers discuss—cells, animals, and (for some drug-class molecules) formal clinical trials. It is not a promise of results for any individual.
“Reported” means described in the literature, not recommended for personal use. Our peptides are for laboratory research only.
Metabolic peptides in this category are investigated for appetite signalling, incretin pathways, and energy balance in research models. Literature emphasises mechanisms rather than lifestyle advice.
Below are mechanistic bullet points as they appear in our product reference material -useful for researchers comparing pathways. They are not simplified health claims.
Storage: Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. ~5% degradation per year refrigerated. - see our storage guide for best practices on temperature, light, and shelf life.
Typical research dosing discussion (literature-style): 0.25–2.4 mg subcutaneously (dose escalation) · Once weekly subcutaneous injection · t½ = 159–195 h (~8 days); Tmax = 24–72 h (median); albumin binding via C20 fatty diacid (analogous to semaglutide); dose escalation: 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg, each maintained 4 weeks. CagriSema uses co-formulated 2.4/2.4 mg in single injection. Currently in late-phase clinical trials.
For preparation, follow the step-by-step reconstitution guide and use the reconstitution calculator to confirm draw volumes. Review subcutaneous injection basics for technique, and always verify batch purity by reading the COA.
What is Cagrilintide in plain language?
Cagrilintide is a research peptide we catalogue under “Fat Loss / Metabolic.” This article explains how scientists discuss it in published literature and what study types usually appear—not as a consumer product claim.
Does this page give medical advice or dosing instructions for Cagrilintide?
No. Content is for laboratory and research literacy only. It does not diagnose, treat, or prevent disease, and is not a dosing guide.
Where can I see purity, variants, and pricing for Cagrilintide?
Use the “View product” button to open the canonical shop listing for Cagrilintide, where specifications and research SKU details are shown.
What about online case reports, before-and-after stories, or forum “logs” for Cagrilintide?
Those sources are not peer-reviewed evidence. This guide focuses on preclinical literature and, where relevant, formal clinical trial programmes for drug-class molecules. Anecdotes may be interesting culturally; they are not a safe basis for dosing or medical decisions.
Open the shop listing for variants, purity notes, and research SKU details.
View productAlso known as: AM833, Cagrilintide Acetate, Long-Acting Amylin Analogue, NN9838, CagriSema Component, Novo Nordisk Cagrilintide